CRB Monitor Securities Database Updates
During the week of Monday November 15, 2021, CRB Monitor’s research team made several updates to securities’ information and added source documents & relevant news articles to the CRB Monitor database. Here is a summary of the updates for the Week of Monday November 15, 2021:
|
Tier |
Total # |
Active / Inactive |
Added |
Removed |
Net Change |
|
Tier 1A |
106 |
88 / 18 |
+0 | -0 | +0 |
|
Tier 1B |
684 |
577 / 107 |
+1 |
-0 | +1 |
|
Tier 2 |
347 |
321 / 26 |
+1 |
-1 | +0 |
|
Tier 3 |
544 |
525 / 19 |
+2 |
-0 |
+2 |
|
Total Issuances |
1,681 |
1,511 / 170 |
+4 |
-1 |
+3 |
|
Total Issuers |
1,385 |
- |
+4 |
-1 |
+3 |
- Added 1 Tier 1B Security:
- +1 = New CRB ("Doseology Sciences Inc.")
- Added 1 Tier 2 Security & Removed 1 Tier 2 Security:
- +1 = New CRB ("Cellular Goods PLC")
- -1 = Remove from Database & Add to the Watchlist: "Ficaar, Inc." (Rationale = Previously involved in the cannabis industry whereby it leased properties to cannabis cultivators in the United States. However, recently completed a merger and "as a result, changed its business focus from engaging in the cannabis industry.” - No longer has any connection to the cannabis industry and/or intent to enter it.)
- Added 2 Tier 3 Securities:
- +1 = New CRB ("Virpax Pharmaceuticals, Inc.")
- +1 = New CRB ("Flexible Solutions International, Inc.")
All newly-identified CRBs during the week:
|
Company Name |
Tier |
Sector |
Description |
|
| 1B | Owner/Investor | Doseology is a diversified life sciences company focusing on functional mushroom products for the health and wellness markets. Through its subsidiary, holds a Canadian Federal Nursery License for an indoor cannabis nursery and for the cultivation/sale of cannabis mothers/clones in Canada. |
|
|
|
(LSE: CBX) |
2 | Pharma & Biotech |
Cellular Goods PLC is a UK-based consumer cannabinoid company. Cellular Goods is a provider of premium consumer pharmaceutical products based on lab-made cannabinoids. |
|
| 3 | Pharma & Biotech |
Specializes in developing product candidates for pain management, CNS disorders and anti-viral indications; Acquired the right to develop, manufacture, market and sell a molecular envelope platform technology for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in adults and children. |
|
|
| 3 | Pharma & Biotech |
Develops, manufactures, and markets specialty chemicals, which slow the evaporation of water; Holds an equity investment in a California-based company which is involved in the development of cannabinoids for consumer and pharmaceutical applications. |
|